GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung disorder.

The British drugmaker announced the trial win using topline data from its MATINEE study for COPD patients with chronic bronchitis and/or emphysema who were on inhaled maintenance therapy.

Data up to 104 weeks suggested that those on Nucala plus inhaled maintenance therapy indicated a statistically significant and clinically meaningful reduction in the annualized rate of moderate/severe exacerbations versus placebo, thus meeting the study’s primary goal.

As for tolerability, the early data suggested that Nucala performed in line with its known safety profile.

Approved for severe asthma and other conditions such as chronic rhinosinusitis, Nucala is a major asset in GSK’s (GSK) respiratory/immunology portfolio. The monoclonal antibody added £1.7B ($2.2B) in revenue for the company in 2023 with ~16% YoY growth.